Loading patent…
AssigneeCallisto Pharmaceuticals
InventorsKunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
Estimating the term…
A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.
A peptide consisting essentially of the amino acid sequence of any one of SEQ ID NO:2-SEQ ID NO:21.
A method for preventing or treating primary or metastatic cancer or polyps in a patient comprising administering to said patient an effective dosage of a guanylate cyclase receptor agonist having the sequence of any one of SEQ ID NO:2-SEQ ID NO:21.
A method for treating metastatic cancer in a patient comprising administering to said patient an effective dosage of a guanylate cyclase receptor agonist selected from the group consisting of:
A method for treating primary cancers other than colon cancer in a patient, comprising administering to said patient an effective dosage of a guanylate cyclase receptor agonist selected from the group consisting of:
A method of treating a patient for colon cancer or polyps comprising administering to said patient an effective dose of an inhibitor of cGMP-dependent phosphodiesterase either concurrently or sequentially with uroguanylin, guanylin or E. coli ST peptide.
A method for preventing or treating inflammation in a patient comprising administering to said patient an effective dosage of a guanylate cyclase receptor agonist having the sequence of any one of:
A method of treating a patient for primary or metastatic cancer, polyps or inflammation comprising administering to said patient:
A pharmaceutical composition in unit dose comprising a guanylate cyclase receptor agonist peptide having the sequence of any one of SEQ ID NOs:2-21 present in a therapeutically effective amount.
A pharmaceutical composition in unit dose form comprising:
A method of inducing apoptosis in the cells of a subject, comprising administering to said subject an effective amount of agonist peptide having the sequence of any one of SEQ IDNO:2-SEQ IDNO:21.
A method of inducing apoptosis in the cells of a subject, comprising administering to said subject an effective amount of uroguanylin, guanylin or E. coli ST peptide for cancers other than colon cancer.
A peptide conjugate comprising polyethylene glycol (PEG) attached to a peptide having the sequence of any of:
Dependencies are inferred from the claim text.